A consensus Covid-19 immune signature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis
暂无分享,去创建一个
J. Mason | M. Shankar-Hari | K. Babalola | P. Vantourout | A. Hayday | P. Peterson | C. Graham | K. Doores | S. Kamdar | A. Laing | M. Greco | J. Edgeworth | K. Bisnauthsing | A. Lorenc | K. Kisand | Abhishek Das | I. del Molino del Barrio | M. Fish | L. Monin | M. Muñoz-Ruiz | Duncan R. McKenzie | T. Hayday | Isaac Francos-Quijorna | Magdalene Joseph | Daniel Davies | Richard Davis | Aislinn Jennings | I. Zlatareva | Yin Wu | Vasiliki Sofra | Florencia Cano | E. Theodoridis | Joshua Freedman | S. Gee | Sarah Ryan | Eva Bugallo-Blanco | Liis Haljasmägi | L. Martinez | B. Merrick | Kate Brooks | Mohammad A A Ibrahim | J. Cason | C. Mant | J. Seow | F. Rosa | Julie Nuo En Chan | F. L. Gomez | Sultan Abdul- Jawad | Irene del Molino del Barrio | A. Jennings | L. Haljasmägi | Mohammad A. A. Ibrahim | Iva Zlatareva | Shraddha Kamdar | Adam G. Laing | Matthew Fish
[1] S. Weiss. Forty years with coronaviruses , 2020, The Journal of experimental medicine.
[2] Hong Yang,et al. Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study , 2011, The Journal of Immunology.
[3] M. Tsai,et al. Basophil-derived tumor necrosis factor can enhance survival in a sepsis model in mice , 2018, Nature Immunology.
[4] Carl H. June,et al. Cytokine release syndrome in severe COVID-19 , 2020, Science.
[5] Aaron J. Wilk,et al. A single-cell atlas of the peripheral immune response to severe COVID-19 , 2020, medRxiv.
[6] A. Bertoletti,et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection , 2016, Vaccine.
[7] Sasikanth Manne,et al. Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions , 2020, bioRxiv.
[8] J. Manus. [Lessons from SARS]. , 2003, Revue de l'infirmiere.
[9] Reiner Schulz,et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events , 2016, Nature Immunology.
[10] A. Casrouge,et al. Discrimination of agonist and antagonist forms of CXCL10 in biological samples , 2012, Clinical and experimental immunology.
[11] Lijuan Xiong,et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.
[12] Aaron M. Rosenfeld,et al. Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection , 2020, bioRxiv.
[13] Michel Theron,et al. An interferon‐γ‐related cytokine storm in SARS patients† , 2004, Journal of medical virology.
[14] Ritesh Gupta,et al. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[15] Zhigang Tian,et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[16] Jing Yuan,et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.
[17] S. Lapinsky,et al. Pro/con clinical debate: Steroids are a key component in the treatment of SARS , 2004, Critical care.
[18] Lei Liu,et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.
[19] P. Kresl. Lessons from the Past and a Look to the Future , 2007 .
[20] S. Perlman,et al. Another Decade, Another Coronavirus , 2020, The New England journal of medicine.
[21] B. Casserly,et al. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. , 2008, Clinics in chest medicine.
[22] D. Chiumello,et al. COVID-19 pneumonia: ARDS or not? , 2020, Critical Care.
[23] M. Shankar-Hari,et al. Goodbye SIRS? Innate, trained and adaptive immunity and pathogenesis of organ dysfunction , 2020, Medizinische Klinik - Intensivmedizin und Notfallmedizin.
[24] Lubka T. Roumenina,et al. Complement System Part II: Role in Immunity , 2015, Front. Immunol..
[25] A. Folgori,et al. Antigen‐specific CD8 T cells in cell cycle circulate in the blood after vaccination , 2019, Scandinavian journal of immunology.
[26] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[27] E. Crivellato,et al. Mast Cells and Basophils: A Potential Link in Promoting Angiogenesis during Allergic Inflammation , 2009, International Archives of Allergy and Immunology.
[28] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[29] M. Netea,et al. Immunological memory: lessons from the past and a look to the future , 2016, Nature Reviews Immunology.
[30] M. Kikkert,et al. Host Factors in Coronavirus Replication , 2017, Current topics in microbiology and immunology.
[31] Dong-Dong Wu,et al. Dendritic Cells in Sepsis: Pathological Alterations and Therapeutic Implications , 2017, Journal of immunology research.
[32] K. Chatterjee,et al. Characterization of biological variation of peripheral blood immune cytome in an Indian cohort , 2019, Scientific Reports.
[33] Sara Invitto,et al. Current state of the science , 2015 .
[34] J. M. Crawford,et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.
[35] B. Pulendran,et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. , 2014, Cell host & microbe.
[36] J. Joh,et al. Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] Bali Pulendran,et al. Immunological mechanisms of vaccination , 2011, Nature Immunology.
[38] Guangyou Duan,et al. A prospective observational cohort study , 2016 .
[39] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[40] I. Wakefield,et al. Influenza vaccination and the elderly. , 1990, BMJ.
[41] L. Saif. Animal coronavirus vaccines: lessons for SARS. , 2004, Developments in biologicals.
[42] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[43] Yan Peng,et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.
[44] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[45] M. Ravid,et al. A Six-Year Follow-up Study , 2016 .
[46] E. Fredlund,et al. Mass Cytometry and Topological Data Analysis Reveal Immune Parameters Associated with Complications after Allogeneic Stem Cell Transplantation. , 2017, Cell reports.
[47] J. McElhaney,et al. Immunosenescence: Influenza vaccination and the elderly. , 2014, Current opinion in immunology.
[48] Miriam Merad,et al. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.
[49] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[50] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[51] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[52] Linqi Zhang,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.
[53] M. Merad,et al. Immunology of COVID-19: Current State of the Science , 2020, Immunity.
[54] A. Hayday,et al. Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood☆☆☆ , 2020, Journal of autoimmunity.
[55] P. Horby,et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.